Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ObsEva SA
  6. News
  7. Summary
    OBSV   CH0346177709

OBSEVA SA

(OBSV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant, an Investigational Agent Being Evaluated as A First-In-Class Treatment for Preterm Labor

07/27/2021 | 01:00am EDT

Organon and ObsEva announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2a (PGF2a) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions. If approved, it has potential to be a first-in-class innovation for this common and serious condition with no approved therapies for acute treatment of preterm labor in the United States. Organon intends to work with the scientific and medical communities and regulatory authorities in major markets, including the United States, to advance the clinical development and registration of ebopiprant. Under the terms of the agreement, Organon will gain exclusive worldwide rights to develop and commercialize ebopiprant. ObsEva is entitled to receive tiered double-digit royalties on commercial sales as well as up to $500 million in upfront and milestone payments including $25 million to be paid at signing, up to $90 million in development and regulatory milestones and up to $385 million sales based milestones. Goldman Sachs acted as exclusive financial advisor to ObsEva.


© S&P Capital IQ 2021
All news about OBSEVA SA
09/15OBSEVA : Seeks US FDA Nod for Uterine Fibroids Drug; Shares Up 5%
MT
09/15OBSEVA : Submits New Drug Application to FDA for Uterine Fibroids Drug Linzagoli..
MT
09/15OBSEVA : Announces Submission of New Drug Application to U.S. FDA for Linzagolix..
AQ
09/15PRESS RELEASE : ObsEva Announces Submission of New Drug Application to U.S. FDA ..
DJ
09/15ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagoli..
CI
09/07PRESS RELEASE : ObsEva to Present at the H.C. Wainwright 23rd Annual Global Inve..
DJ
09/07OBSEVA : to Present at the H.C. Wainwright 23rd Annual Global Investment Confere..
AQ
08/05OBSEVA : INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Form 6-..
PU
08/05OBSEVA : Q2 Half Year Report 2021
PU
08/05OBSEVA : Q2 Loss Narrows, Operating Expenses Rise
MT
More news
Analyst Recommendations on OBSEVA SA
More recommendations
Financials (USD)
Sales 2021 0,01 M - -
Net income 2021 -73,5 M - -
Net cash 2021 41,3 M - -
P/E ratio 2021 -3,09x
Yield 2021 -
Capitalization 228 M 228 M -
EV / Sales 2021 20 712x
EV / Sales 2022 9,79x
Nbr of Employees 43
Free-Float 62,9%
Chart OBSEVA SA
Duration : Period :
ObsEva SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OBSEVA SA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,06 $
Average target price 19,00 $
Spread / Average Target 521%
EPS Revisions
Managers and Directors
Brian O'Callaghan Chief Executive Officer & Director
David Renas Chief Financial Officer
Frank A. G. M. Verwiel Chairman
Jean-Pierre Gotteland Chief Scientific Officer, Head-R&D
Elizabeth Ijeoma Onyemelukwe Garner Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
OBSEVA SA47.60%228
GILEAD SCIENCES, INC.23.17%89 973
BIONTECH SE335.78%85 800
REGENERON PHARMACEUTICALS34.96%67 787
WUXI APPTEC CO., LTD.28.41%64 886
VERTEX PHARMACEUTICALS-20.09%48 996